| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.33 MB | Adobe PDF |
Authors
Advisor(s)
Abstract(s)
Nos últimos anos, os canabinóides têm sido alvo de estudo na área da medicina
veterinária devido às suas propriedades anti-inflamatórias e analgésicas. Contudo, a sua
utilização continua a ser alvo de estudo em animais de companhia. A presente
dissertação foi realizada com base nos dados obtidos no Hospital Veterinário da
Arrábida, durante o período de um mês, com a finalidade de verificar a tolerabilidade,
segurança e efeitos secundários associados à administração de óleo de canabidiol na
dose anti-inflamatória em cães. Vinte e quatro cães com alterações osteoarticulares
foram avaliados por um médico veterinário diplomado e submetidos ao estudo, com
monitorização de análises séricas alanina aminotransferase e fosfatase alcalina (ALT e
ALKP) em T0 (primeiro dia), T1 (décimo quinto dia) e T2 (trigésimo dia). Em T0 e T2
foram também avaliados a partir de check-list neurológica e quanto aos sinais
gastrointestinais. A vinte e quatro cães, com idade média de 7.8 (±2.8) anos e 20.5
(±11.9) kg, foi prescrito 5 mg/kg BID de óleo de canabidiol durante quatro semanas.
Foram ainda realizados questionários aos tutores em T2 relativamente à palatibilidade e
tolerabilidade. Na check-list neurológica em T2, 95.84% (23/24) não apresentaram
alterações. Relativamente às transaminases, apenas 16.7% (4/24) durante 4 semanas não
demonstraram alteração, verificando-se fosfatase alcalina aumentada em 70.8% (17/24)
(em T1) e em 20.8% (5/24) (em T2), fundamentando a monitorização sérica ao longo
das 4 semanas terapêuticas. Aproximadamente 50% (12/24) dos tutores indicaram o
produto palatável e em 37.5% (9/24) observou-se aumento de apetite. O stress
gastrointestinal foi residual. Apesar do estudo realizado sugerir boa tolerabilidade,
segurança e promotor de bem-estar à administração de óleo de canabidiol, o estudo
deve ser continuado.
In the last years, cannabinoids (CBD) have been under several studies in the veterinary medicine field, due to its analgesic and anti-inflammatory properties. However, its use is still under investigation in small animals. This dissertation was performed regarding data obtained from Arrábida Veterinary Hospital, during 1 month, to test tolerability, safety and side effects concerning the administration of CBD oil in dogs using anti-inflammatory dose. Twenty-four dogs with osteoarticular disease were evaluated by an ECVSMR diplomate and admitted to the study with blood measurement of ALT and ALKP at T0 (1st day), T1 (15th day) and T2 (30th day). In T0 and T2, they were evaluated with a neurological exam check-list and registration of gastrointestinal signs. For 24 dogs, with a mean age of 7.8 (±2.8) years and a mean weight of 20.5 (±11,9) kg, it was prescribed 5 mg/kg of CBD oil (BID), during 4 weeks. The owners also answered a form about tolerability and palatability in T2. Regarding neurological check-list in T2, 95.84% (23/24) didn’t show intolerance signs, although only 16.7% (4/24) didn’t show transaminase alterations after the 4 weeks administration. ALKP values were increased in 70.8% (in T1) and 20.8% (in T2), supporting the importance of serum monitoring during 4 therapeutic weeks. Nearly 50% of the owners reported that the product was palatable and in 37.5% there was an increase in appetite. Gastrointestinal stress was residual. Despite the study suggesting good tolerability, safety and well-being promotion of the CBD oil, the study must be continued.
In the last years, cannabinoids (CBD) have been under several studies in the veterinary medicine field, due to its analgesic and anti-inflammatory properties. However, its use is still under investigation in small animals. This dissertation was performed regarding data obtained from Arrábida Veterinary Hospital, during 1 month, to test tolerability, safety and side effects concerning the administration of CBD oil in dogs using anti-inflammatory dose. Twenty-four dogs with osteoarticular disease were evaluated by an ECVSMR diplomate and admitted to the study with blood measurement of ALT and ALKP at T0 (1st day), T1 (15th day) and T2 (30th day). In T0 and T2, they were evaluated with a neurological exam check-list and registration of gastrointestinal signs. For 24 dogs, with a mean age of 7.8 (±2.8) years and a mean weight of 20.5 (±11,9) kg, it was prescribed 5 mg/kg of CBD oil (BID), during 4 weeks. The owners also answered a form about tolerability and palatability in T2. Regarding neurological check-list in T2, 95.84% (23/24) didn’t show intolerance signs, although only 16.7% (4/24) didn’t show transaminase alterations after the 4 weeks administration. ALKP values were increased in 70.8% (in T1) and 20.8% (in T2), supporting the importance of serum monitoring during 4 therapeutic weeks. Nearly 50% of the owners reported that the product was palatable and in 37.5% there was an increase in appetite. Gastrointestinal stress was residual. Despite the study suggesting good tolerability, safety and well-being promotion of the CBD oil, the study must be continued.
Description
Keywords
alanina aminotransferase canabidiol dor fosfatase alcalina tolerabilidade alkaline phosphatase pain tolerability